Takeda executive sells ADSs to cover tax obligations

TAKEDA PHARMACEUTICAL CO LTD director and President, R&D Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD director and President, R&D Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, he holds 766,569 ADSs directly and 281,307 ADSs indirectly through a trust.

Insider Trade Summary

Net Seller: 165,393 shares

Net Sell 2 txns

Insider Plump Andrew Stewart

Role President, R&D

Sold 165,393 shs ($2.83M)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	165,393	$17.10	$2.83M
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 766,569 shares (Direct); American Depositary Shares — 281,307 shares (Indirect, By Trust)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 165,393 American Depositary Shares Weighted average sale price: $17.10 per share Direct holdings after transaction: 766,569 American Depositary Shares +1 more

4 metrics

Shares sold 165,393 American Depositary Shares Mandatory sale to cover taxes on 2026-08-10

Weighted average sale price $17.10 per share Price for ADS sale on 2026-08-10

Direct holdings after transaction 766,569 American Depositary Shares Direct ownership following the reported sale

Indirect holdings by trust 281,307 American Depositary Shares Indirect ownership described as By Trust

Key Terms

American Depositary Shares, mandatory sale to cover taxes, weighted average price, By Trust

4 terms

American Depositary Shares financial

"security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

By Trust financial

"nature_of_ownership": "By Trust""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TAK (Takeda Pharmaceutical) report for Andrew Stewart Plump?

Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares of Takeda Pharmaceutical on 2026-08-10. The shares were sold to cover tax obligations from vesting equity awards.

At what price were the TAK American Depositary Shares sold in this Form 4?

The shares were sold at a weighted average price of $17.10 per ADS. A footnote states full details of the number of shares sold at each separate price within the reported ranges are available upon request.

Why did Andrew Stewart Plump sell Takeda (TAK) shares according to the filing?

The Form 4 states the transaction was a mandatory sale to cover taxes associated with the vesting of equity awards held by Andrew Stewart Plump, rather than a discretionary open-market sale.

How many Takeda (TAK) ADSs does Andrew Stewart Plump hold after the reported sale?

After the transaction, Andrew Stewart Plump holds 766,569 ADSs directly and 281,307 ADSs indirectly through a trust, as reported in the Form 4 holdings information.

Is any of Andrew Stewart Plump’s Takeda (TAK) ownership held indirectly?

Yes. The Form 4 shows an indirect holding of 281,307 American Depositary Shares described as held “By Trust”, in addition to his directly held ADS position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plump Andrew Stewart

(Last) (First) (Middle)

300 MASSACHUSETTS AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		165,393	D	$17.1(2)	766,569	D
American Depositary Shares								281,307	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Andrew S Plump	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)